Article
Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity
2020-07-09
Abstract excerpt
<h4>Background: </h4> : HSG4112 is a clinical-stage drug candidate for the treatment of obesity. Here, we report its discovery and preclinical efficacy. <h4>Methods: </h4> : In high-fat diet (HFD)-induced obese male C57BL/6J mice, we tested the weight loss effect of synthetic compounds derived from a structure-activity relationship (SAR) study of glabridin, a natural compound known to reduce body weight and inf...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 2908a994-c97b-5f58-a17b-4aa70874c0d0
- DOI
- 10.22541/au.158282438.81737534/v2
